Analysis of the EGFR gene to identify NSCLC patients who may be eligible for TKI therapies. This assay detects mutations in the EGFR gene that confer TKI sensitivity and TKI resistance.
Submit a formalin-fixed, paraffin-embedded (FFPE) tissue block
FFPE tissue block
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
Cobas EGFR Mutation Test v2 (IVD, Roche)
An interpretive report will be provided